Neptune Reports Year End Financial Results

Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results

Laval, Quebec, Canada, September 28, 2007 - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB), is pleased to report its financial results for the fiscal year ended May 31, 2007. During the last fiscal year, Neptune improved its productivity and operational profitability while continuing its business development strategy to penetrate the American, European and Asian markets, resulting in sustainable sales growth.

Financial Results and Highlights:

• Sales increased by 18% to $8,126,000 from $6,912,000 in the preceding fiscal year.
• EBITDA increased by 43% to $1,504,000 from $1,049,000 in the preceding fiscal year, representing a third consecutive year with a positive EBITDA.
• EBITDA margin reached 18.5%, compared to 15.2% in the preceding fiscal year.
• Excluding stock-based compensation expenses, Neptune would have realized earnings of $152,000 instead of a loss of $2,677,000 in the fiscal year ended May 31, 2007. Excluding stock-based compensation expenses and an extraordinary gain from the settlement of debentures, Neptune would have realized a loss of $1,574,000 instead of a loss of $886,000 in the fiscal year ended May 31, 2006.

“We believe that the evaluation model and accounting method for stock-based compensation expenses are not appropriate for small capitalization fast growing companies. They do not bring the accounting value of stock-based compensation closer to the market value, as they should and as they were implemented for”, stated Xavier Harland, Director of Finance.

“Neptune has managed to increase its EBITDA by $455,000 with a $1.2M increase in sales, confirming its improvement in operational efficiency”, stated André Godin, Vice-President, Administration and Finance.

Neptune continues to strongly support its strategic development plan to pursue partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. In accordance with its plan, Neptune has signed agreements with Nestlé and Yoplait, paving the way for its entrance into the global functional food market. Neptune is in negotiations with pharmaceutical companies with the short-term objective of penetrating the pharmaceutical market.

About Neptune Technologies & Bioressources Inc. https://www.neptunebiotech.com/
Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.